ベータ神経成長因子（ベータNGFまたはNGF）のパイプライン標的は14分子近くを構成します。そのうち約14個の分子が企業によって開発されています。本レポートは、ベータ神経成長因子（ベータNGFまたはNGF）標的治療薬に関する包括的情報を、適応症、開発ステージ、作用機序（MoA）、投与経路（RoA）、および分子タイプ別の分析とともに概説しています。
ベータ神経成長因子（ベータNGFまたはNGF）- 神経成長因子は、特定の標的ニューロンの成長、維持、増殖、および生存の制御に関与する神経栄養因子です。メタロプロテアーゼによる血小板糖蛋白質VIの蛋白分解を阻害します。フェーズIII、フェーズII、フェーズI、IND/CTA申請中、前臨床、創薬の各段階で各社が開発した分子は、それぞれ1、3、1、2、5、2となっています。本レポートは、中枢神経系、心血管、眼科、皮膚科、血液疾患、免疫学および筋骨格系障害の治療領域からの以下の適応症製品をカバーしています：痛み、癌性疼痛、変形性関節症の痛み、筋萎縮性側索硬化症、腰痛、心臓停止、糖尿病性神経障害性疼痛、緑内障、角膜炎、肺移植拒絶反応、心筋梗塞、視神経損傷、変形性関節症、パーキンソン病、末梢神経損傷、手術後疼痛、褥瘡、網膜色素変性症（網膜炎）、シッカ症候群（シェーグレン）、鎌状赤血球病。
さらに、それぞれの稼働中および休止中または中止されたプロジェクトでベータ神経成長因子（ベータNGFまたはNGF）を対象とした治療法の開発に関与する主要なプレーヤーをレビューします。独自のデータベース、企業/大学のWebサイト、臨床試験レジストリ、会議、SECファイリング、投資家向けプレゼンテーション、および企業/大学のサイトや業界固有のサードパーティソースからの注目のプレスリリースから得られたデータと情報に基づいています。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Akeso Inc
AstraZeneca Plc
Chengdu Easton Biopharmaceuticals Co Ltd
Dartsbio Pharmaceutical (Guangdong) Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Regeneron Pharmaceuticals Inc
Shandong Boan Biotechnology Co Ltd
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
AK-115 - Drug Profile
Product Description
Mechanism Of Action
DS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-9001A - Drug Profile
Product Description
Mechanism Of Action
fasinumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
MT-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
TNM-009 - Drug Profile
Product Description
Mechanism Of Action
TNM-010 - Drug Profile
Product Description
Mechanism Of Action
TNM-011 - Drug Profile
Product Description
Mechanism Of Action
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
History of Events
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Feb 10, 2022: Approval of clinical trial of NGF monoclonal antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain
Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA
Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug
May 12, 2010: Regeneron Provides Initial Data On REGN475
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Akeso Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2022
Pipeline by Dartsbio Pharmaceutical (Guangdong) Co Ltd, 2022
Pipeline by Fujimoto Pharmaceutical Corp, 2022
Pipeline by MimeTech Srl, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Pipeline by Staidson BioPharma Inc, 2022
Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
